Compare · MRK vs PTIX
MRK vs PTIX
Side-by-side comparison of Merck & Company Inc. (MRK) and Protagenic Therapeutics Inc. (PTIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PTIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $327.94B, about 17582.4x PTIX ($18.7M).
- Over the past year, MRK is up 60.7% and PTIX is down 72.8% - MRK leads by 133.5 points.
- MRK has been more active in the news (15 items in the past 4 weeks vs 4 for PTIX).
- MRK has more recent analyst coverage (25 ratings vs 1 for PTIX).
- Company
- Merck & Company Inc.
- Protagenic Therapeutics Inc.
- Price
- $132.90+1.97%
- $0.73-44.06%
- Market cap
- $327.94B
- $18.7M
- 1M return
- +10.00%
- +0.00%
- 1Y return
- +60.70%
- -72.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 15
- 4
- Recent ratings
- 25
- 1
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Protagenic Therapeutics Inc.
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Latest MRK
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $5,942,369 worth of shares (45,320 units at $131.12), decreasing direct ownership by 29% to 110,167 units (SEC Form 4)
- Merck upgraded by Daiwa Securities with a new price target
- EVP&Pres, Merck Animal Heallth Deluca Richard R. sold $788,773 worth of shares (6,050 units at $130.38), decreasing direct ownership by 4% to 155,487 units (SEC Form 4)
- EVP & Pres. MMD Maraldo David R. exercised 18,706 shares at a strike of $82.25 and sold $2,407,797 worth of shares (18,706 units at $128.72) (SEC Form 4)
- EVP,Chief Info&Digital Officer Williams David Michael exercised 52,847 shares at a strike of $74.49 and sold $6,805,145 worth of shares (52,847 units at $128.77), increasing direct ownership by 0.00% to 31,716 units (SEC Form 4)
- EVP, Access, Policy & Comms Guindo Chirfi sold $1,965,000 worth of shares (15,000 units at $131.00), decreasing direct ownership by 24% to 46,613 units (SEC Form 4)
- SEC Form 10-Q filed by Merck & Company Inc.
- SEC Form 13F-HR filed by Merck & Company Inc.
- U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season
- Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment
Latest PTIX
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $710 worth of shares (2,220 units at $0.32), increasing direct ownership by 7% to 34,199 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $151 worth of shares (685 units at $0.22), increasing direct ownership by 2% to 31,979 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $1,294 worth of shares (5,000 units at $0.26), increasing direct ownership by 19% to 31,294 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF. Armen Garo H bought $4,806 worth of shares (26,291 units at $0.18) (SEC Form 4)
- SEC Form NT 10-K filed by Protagenic Therapeutics Inc.
- Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
- Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
- Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market